Aquestive Therapeutics, Inc.

For the period ended Jun 30, 2026. Filed Aug 11, 2026.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Jun 30, 2026 · Filed Aug 11, 2026

AQST$3.54-1.9%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Item 6. Exhibits

The exhibits listed below are filed or furnished as part of this report.

Number	Description
4.1	Form of Warrant (filed as Exhibit 4.2 to the Registration Statement on Form S-3 of the Company as filed on June 26, 2026, and incorporated by reference herein).
10.1	Warrant Issuance Agreement, dated as of May 12, 2026, between Oaktree Capital Management, L.P. and Aquestive Therapeutics, Inc. (filed as Exhibit 10.1 to the Registration Statement on Form S-3 of the Company as filed on June 26, 2026, and incorporated by reference herein).
10.2†	Credit Agreement and Guaranty, dated as of May 12, 2026, by and among Aquestive Therapeutics, Inc., the guarantors from time to time party thereto, the lenders from time to time party thereto, and Oaktree Fund Administration, LLC (filed as Exhibit 10.2 to the Registration Statement on Form S-3 of the Company as filed on June 26, 2026, and incorporated by reference herein).
10.3	Security Agreement, dated as of May 12, 2026, by and among Aquestive Therapeutics, Inc., the borrower’s subsidiaries having acceded thereto pursuant to Section 24, and Oaktree Fund Administration, LLC (filed as Exhibit 10.3 to the Registration Statement on Form S-3 of the Company as filed on June 26, 2026, and incorporated by reference herein).
10.4*†	Second Amendment to License Agreement, dated as of April 20, 2026, by and between Aquestive Therapeutics, Inc. and Atnahs Pharma UK Limited.
10.5*	Lease Agreement dated May 8, 2026 by and between 184 Property Owner, LLC and Aquestive Therapeutics, Inc.
31.1*	Certification of Principal Executive Officer Pursuant to Rules 13a-14(a) and 15d-14(a), as amended, under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 (filed herewith).
31.2*	Certification of Principal Financial Officer Pursuant to Rules 13a-14(a) and 15d-14(a), as amended, under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 (filed herewith).
32.1**	Certification of Principal Executive Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
32.2**	Certification of Principal Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
101.INS*	XBRL Instance Document
101.SCH*	XBRL Taxonomy Extension Schema Document
101.CAL*	XBRL Taxonomy Extension Calculation Linkbase Document
101.DEF*	XBRL Taxonomy Extension Definition Linkbase Document
101.LAB*	XBRL Taxonomy Extension Label Linkbase Document
101.PRE*	XBRL Taxonomy Extension Presentation Linkbase Document
104*	Cover Page Interactive Data File (formatted as Inline XBRL document and contained in exhibit 101)

Filed herewith.

** Furnished herewith.

†Certain portions of this exhibit have been omitted in accordance with Item 601(b)(10)(iv) of Regulation S-K because the omitted information is (i) not material and (ii) the registrant customarily and actually treats that information as private or confidential. The registrant agrees to furnish supplementally an unredacted copy and its materiality and privacy or confidentiality analyses to the SEC upon its request.

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.